<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1665-5044</journal-id>
<journal-title><![CDATA[Revista mexicana de neurociencia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. neurocienc.]]></abbrev-journal-title>
<issn>1665-5044</issn>
<publisher>
<publisher-name><![CDATA[Academia Mexicana de Neurología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1665-50442024000300066</article-id>
<article-id pub-id-type="doi">10.24875/rmn.23000074</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Subependymal giant cell astrocytoma, hereditary versus solitary: clinical, morphological, and immunophenotypic characterization]]></article-title>
<article-title xml:lang="es"><![CDATA[Astrocitoma subependimario de células gigante, hereditario versus solitario: caracterización clínica, morfológica e inmunofenotípica]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Calderón-Garcidueñas]]></surname>
<given-names><![CDATA[Ana L.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Piña-Ballantyne]]></surname>
<given-names><![CDATA[Steven A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez Department of Neuropathology ]]></institution>
<addr-line><![CDATA[ Mexico City]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2024</year>
</pub-date>
<volume>25</volume>
<numero>3</numero>
<fpage>66</fpage>
<lpage>74</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1665-50442024000300066&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1665-50442024000300066&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1665-50442024000300066&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: To compare clinicopathological characteristics of patients with solitary subependymal giant cell astrocytoma (SEGA) at our institution, with those associated to tuberous sclerosis complex (TSC).  Methods: It was a descriptive-retrospective study of surgically treated SEGA patients (2013-2022). Demographic and clinical data were obtained. An immunohistochemistry (IHC) panel was applied: GFAP, neurofilaments, hamartin, tuberin, Ki67, nestin, OCT-4, INI-1, STAT-6, CK-AE1/AE3, TTF1, and YAP-1. Descriptive statistical was used.  Results: 4 patients were studied: Two women, 23 and 25 years old, diagnosed as TSC patients at 10 and 12 years of age, and two men with solitary SEGA (18 and 46 years old). Tumors were positive to GFAP, NF, nestin, and TTF1. Cytoplasmic STAT6 and CK stains was observed in all patients. 2/4 cases showed YAP-1 nuclear expression. TSC patients retained INI-1 nuclear expression, while solitary SEGAs lost it.  Conclusions: SEGA is a glioneuronal tumor that expresses markers of neuroepithelial stem cells and cytokeratins. Its diagnosis must be supported with a minimal IHC panel: GFAP, neurofilaments, synaptophysin, nestin and TTF1. Morphological differences were observed between the TSC related and solitary SEGAs and in INI1 expression. Nuclear expression of YAP-1 in 2/4 tumors, opens the possibility of research for combined use of YAP and mTOR regulators in the management of SEGA.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Comparar las características clínico-patológicas de los pacientes con astrocitoma subependimario de células gigantes (SEGA) solitario y el asociado al complejo de esclerosis tuberosa (TSC).  Métodos: Se realizó un estudio descriptivo-retrospectivo de pacientes con SEGA tratados quirúrgicamente (2013-2022). Se obtuvieron datos demográficos y clínicos. Se aplicó un panel de inmunohistoquímica (IHC): GFAP, neurofilamentos, hamartina, tuberina, Ki67, nestina, OCT-4, INI-1, STAT-6, CK-AE1/AE3, TTF1 y YAP-1. Se utilizó estadística descriptiva.  Resultados: Se estudiaron 4 pacientes: dos mujeres de 23 y 25 años, diagnosticadas como pacientes con TSC a los 10 y 12 años, y dos hombres con SEGA solitario (18 y 46 años). Los tumores fueron positivos para GFAP, NF, nestina y TTF1. Se observó positividad citoplásmica de STAT6 y CK en todos los pacientes. 2/4 casos mostraron expresión nuclear YAP-1. Los pacientes con TSC conservaron la expresión nuclear de INI-1, mientras que los SEGA solitarios la perdieron.  Conclusiones: SEGA es un tumor glioneuronal que expresa marcadores de células madre neuroepiteliales y citoqueratinas. Su diagnóstico debe apoyarse en un panel IHC mínimo: GFAP, neurofilamentos, sinaptofisina, nestina y TTF1. Se observaron diferencias morfológicas entre los SEGA solitarios y los relacionados con TSC y en la expresión de INI1. La expresión nuclear de YAP-1 en 2/4 tumores es un hallazgo nuevo, que abre la posibilidad del uso combinado de reguladores YAP y mTOR en el manejo de SEGA.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Subependymal giant cell astrocytoma]]></kwd>
<kwd lng="en"><![CDATA[Tuberous sclerosis complex]]></kwd>
<kwd lng="en"><![CDATA[Nestin]]></kwd>
<kwd lng="en"><![CDATA[YAP-1]]></kwd>
<kwd lng="en"><![CDATA[INI-1]]></kwd>
<kwd lng="en"><![CDATA[Immunohistochemistry]]></kwd>
<kwd lng="es"><![CDATA[Astrocitoma subependimario de células gigantes]]></kwd>
<kwd lng="es"><![CDATA[Complejo de esclerosis tuberosa]]></kwd>
<kwd lng="es"><![CDATA[Nestina]]></kwd>
<kwd lng="es"><![CDATA[YAP-1]]></kwd>
<kwd lng="es"><![CDATA[INI-1]]></kwd>
<kwd lng="es"><![CDATA[Inmunohistoquímica]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Louis]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
<name>
<surname><![CDATA[Perry]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wesseling]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Brat]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cree]]></surname>
<given-names><![CDATA[IA]]></given-names>
</name>
<name>
<surname><![CDATA[Figarella-Branger]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The 2021 WHO classification of tumors of the central nervous system:a summary]]></article-title>
<source><![CDATA[Neuro Oncol]]></source>
<year>2021</year>
<volume>23</volume>
<page-range>1231-51</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brat]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subependymal Giant-Cell Astrocytomas. Astrocytic Tumors]]></article-title>
<source><![CDATA[Greenfield's Neuropathology]]></source>
<year>2015</year>
<edition>9th ed</edition>
<page-range>1665-72</page-range><publisher-loc><![CDATA[Florida, United States of America ]]></publisher-loc>
<publisher-name><![CDATA[Taylor and Group]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Doan]]></surname>
<given-names><![CDATA[NB]]></given-names>
</name>
<name>
<surname><![CDATA[Gelsomino]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shabani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Awad]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Best]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subependymal giant cell astrocytoma:a surveillance, epidemiology, and end results program-based analysis from 2004 to 2013]]></article-title>
<source><![CDATA[World Neurosurg]]></source>
<year>2018</year>
<volume>118</volume>
<page-range>263-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salussolia]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Klonowska]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kwiatkowski]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sahin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetic etiologies, diagnosis, and treatment of tuberous sclerosis complex]]></article-title>
<source><![CDATA[Annu Rev Genomics Hum Genet]]></source>
<year>2019</year>
<volume>20</volume>
<page-range>217-40</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buccoliero]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Franchi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Castiglione]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gheri]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Mussa]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Giordano]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subependymal giant cell astrocytoma (SEGA):is it an astrocytoma?Morphological, immunohistochemical and ultrastructural study]]></article-title>
<source><![CDATA[Neuropathology]]></source>
<year>2009</year>
<volume>29</volume>
<page-range>25-30</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Habib]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Obaidi]]></surname>
<given-names><![CDATA[NY]]></given-names>
</name>
<name>
<surname><![CDATA[Nowacki]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pietkun]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Zegarska]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kloskowski]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is mTOR inhibitor good enough for treatment all tumors in TSC patients?]]></article-title>
<source><![CDATA[J Cancer]]></source>
<year>2016</year>
<volume>7</volume>
<page-range>1621-31</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hang]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thyroid transcription factor-1 distinguishes subependymal giant cell astrocytoma from its mimics and supports its cell origin from the progenitor cells. In the medial ganglionic eminence]]></article-title>
<source><![CDATA[Mod Pathol]]></source>
<year>2017</year>
<volume>30</volume>
<page-range>318-28</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dutta]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Suri]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Sarkar]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Garg]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Suri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[TTF- 1:a well-favored addition to the immunohistochemistry armamentarium as a diagnostic marker of SEGA]]></article-title>
<source><![CDATA[World Neurosurg]]></source>
<year>2022</year>
<volume>159</volume>
<page-range>62-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bernal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Arranz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nestin-expressing progenitor cells:function, identity and therapeutic implications]]></article-title>
<source><![CDATA[Cell Mol Life Sci]]></source>
<year>2018</year>
<volume>75</volume>
<page-range>2177-95</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neradil]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Veselska]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nestin as a marker of cancer stem cells]]></article-title>
<source><![CDATA[Cancer Sci]]></source>
<year>2015</year>
<volume>106</volume>
<page-range>803-11</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kandukuri]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gui]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gong]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Application of immunohistochemistry in undifferentiated neoplasms:a practical approach]]></article-title>
<source><![CDATA[Arch Pathol Lab Med]]></source>
<year>2017</year>
<volume>141</volume>
<page-range>1014-32</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calderón-Garcidueñas]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Piña-Ballantyne]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa-Aguilar]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subependymal giant cell astrocytoma non-associated with tuberous sclerosis complex and expression of OCT-4 and INI- 1:a case report]]></article-title>
<source><![CDATA[Cureus]]></source>
<year>2023</year>
<volume>15</volume>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kohashi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Oda]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncogenic roles of SMARCB1/INI1 and its deficient tumors]]></article-title>
<source><![CDATA[Cancer Sci]]></source>
<year>2017</year>
<volume>108</volume>
<page-range>547-52</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Petty]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Dixon-McDougall]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Tyshkovskiy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Maybury-Lewis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chemically induced reprogramming to reverse cellular aging]]></article-title>
<source><![CDATA[Aging (Albany NY)]]></source>
<year>2023</year>
<volume>15</volume>
<page-range>5966-89</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ura]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Togi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ozaki]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hatanaka]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Niida]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Establishment of human induced pluripotent stem cell lines, KMUGMCi006, from a patient with Tuberous sclerosis complex (TSC) bearing mosaic nonsense mutations in the Tuberous sclerosis complex 2 (TSC2) gene]]></article-title>
<source><![CDATA[Stem Cell Res]]></source>
<year>2023</year>
<volume>70</volume>
<page-range>103129</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Leung]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Momenilandi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Pacillo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease]]></article-title>
<source><![CDATA[J Exp Med]]></source>
<year>2023</year>
<volume>220</volume>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Ralte]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Gaekwad]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Santosh]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Shankar]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Sarkar]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subependymal giant cell astrocytoma--a clinicopathological study of 23 cases with special emphasis on histogenesis]]></article-title>
<source><![CDATA[Pathol Oncol Res]]></source>
<year>2004</year>
<volume>10</volume>
<page-range>219-24</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pontes]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mendes]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanical properties of glioblastoma:perspectives for YAP/TAZ signaling pathway and beyond]]></article-title>
<source><![CDATA[Diseases]]></source>
<year>2023</year>
<volume>11</volume>
<page-range>86</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sekido]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Sato]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[NF2 alteration in mesothelioma]]></article-title>
<source><![CDATA[Front Toxicol]]></source>
<year>2023</year>
<volume>5</volume>
<page-range>1161995</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dong]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with Salvador and warts]]></article-title>
<source><![CDATA[Cell]]></source>
<year>2003</year>
<volume>114</volume>
<page-range>445-56</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Terry]]></surname>
<given-names><![CDATA[BK]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Crino]]></surname>
<given-names><![CDATA[PB]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abnormal activation of Yap/Taz contributes to the pathogenesis of tuberous sclerosis complex]]></article-title>
<source><![CDATA[Hum Mol Genet]]></source>
<year>2022</year>
<volume>31</volume>
<page-range>1979-96</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Loh]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yap]]></surname>
<given-names><![CDATA[YS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PI3K/Akt/mTOR inhibitors in breast cancer]]></article-title>
<source><![CDATA[Cancer Biol Med]]></source>
<year>2015</year>
<volume>12</volume>
<page-range>342-54</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
